DexCom - DXCM Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $141.40
Forecasted Upside: 2.46%
Number of Analysts: 14
Breakdown:
0 Sell Ratings
2 Hold Ratings
11 Buy Ratings
1 Strong Buy Ratings

^$138.01 As of 04/25/2024 01:00 AM ET

▲ +0.14 (0.10%)

1 month | 3 months | 12 months

Get New DexCom Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for DXCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DXCM

^$141.40

▲ +2.46% Upside Potential

This price target is based on 14 analysts offering 12 month price targets for DexCom in the last 3 months. The average price target is $141.40, with a high forecast of $165.00 and a low forecast of $100.00. The average price target represents a 2.46% upside from the last price of $138.01.

Current Consensus is Moderate Buy

The current consensus among 14 investment analysts is to moderate buy stock in DexCom. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/2/2022

1 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/31/2023

1 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/1/2023

1 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/30/2023

1 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/28/2023

1 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/26/2024

1 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/26/2024

1 strong buy ratings
11 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/25/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/10/2024	UBS Group	Boost Target	Buy ➝ Buy	$153.00 ➝ $163.00	Low
4/3/2024	Citigroup	Boost Target	Buy ➝ Buy	$148.00 ➝ $161.00	Low
3/12/2024	Royal Bank of Canada	Initiated Coverage	Outperform	$165.00	Low
1/23/2024	Raymond James	Boost Target	Strong-Buy ➝ Strong-Buy	$147.00 ➝ $151.00	Low
1/3/2024	Raymond James	Boost Target	Strong-Buy ➝ Strong-Buy	$131.00 ➝ $147.00	Low
12/19/2023	Piper Sandler	Boost Target	Overweight ➝ Overweight	$135.00 ➝ $150.00	Low
12/13/2023	Wells Fargo & Company	Boost Target	Overweight ➝ Overweight	$110.00 ➝ $136.00	Low
12/4/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$101.00 ➝ $122.00	Low
10/27/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$98.00 ➝ $101.00	Low
10/17/2023	JPMorgan Chase & Co.	Lower Target	Overweight ➝ Overweight	$160.00 ➝ $100.00	Low
10/16/2023	Leerink Partnrs	Reiterated Rating	Outperform		Low
10/16/2023	SVB Leerink	Initiated Coverage	Outperform	$110.00	Low
10/10/2023	Stifel Nicolaus	Lower Target	Buy ➝ Buy	$155.00 ➝ $145.00	Low
10/2/2023	Citigroup	Lower Target		$150.00 ➝ $115.00	Low
9/29/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$131.00 ➝ $98.00	Low
9/15/2023	Raymond James	Lower Target	Strong-Buy ➝ Strong-Buy	$154.00 ➝ $131.00	Low
9/6/2023	UBS Group	Lower Target	Buy ➝ Buy	$175.00 ➝ $138.00	Low
8/21/2023	Robert W. Baird	Lower Target	Outperform ➝ Outperform	$153.00 ➝ $130.00	Low
7/31/2023	Barclays	Boost Target	Equal Weight	$115.00 ➝ $138.00	Low
7/28/2023	Canaccord Genuity Group	Boost Target	Buy	$135.00 ➝ $150.00	Low
7/28/2023	Raymond James	Boost Target		$140.00 ➝ $154.00	Low
7/28/2023	Piper Sandler	Boost Target	Overweight	$150.00 ➝ $160.00	Low
7/28/2023	Oppenheimer	Boost Target		$135.00 ➝ $150.00	Low
7/28/2023	Robert W. Baird	Boost Target		$145.00 ➝ $153.00	Low
7/10/2023	Citigroup	Boost Target		$146.00 ➝ $150.00	Low
6/26/2023	BTIG Research	Boost Target		$134.00 ➝ $150.00	Low
5/30/2023	Morgan Stanley	Initiated Coverage	Equal Weight	$131.00	Low
5/1/2023	Barclays	Boost Target		$110.00 ➝ $115.00	Low
4/28/2023	Stifel Nicolaus	Boost Target		$130.00 ➝ $140.00	Low
4/28/2023	UBS Group	Boost Target		$142.00 ➝ $150.00	Low
4/28/2023	BTIG Research	Boost Target		$132.00 ➝ $134.00	Low
4/28/2023	Raymond James	Boost Target		$138.00 ➝ $140.00	Low
4/17/2023	BTIG Research	Boost Target	Buy	$126.00 ➝ $132.00	Low
4/17/2023	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$127.00 ➝ $138.00	Low
3/28/2023	UBS Group	Initiated Coverage	Buy	$142.00	Low
2/13/2023	Barclays	Boost Target	Equal Weight	$103.00 ➝ $110.00	Low
2/10/2023	Cowen	Boost Target	Outperform	$114.00 ➝ $125.00	Low
1/26/2023	Wolfe Research	Initiated Coverage	Outperform	$121.00	N/A
1/6/2023	Morgan Stanley	Boost Target	Equal Weight	$117.00 ➝ $131.00	Low
12/20/2022	Stifel Nicolaus	Boost Target		$120.00 ➝ $130.00	Low
12/12/2022	Citigroup	Boost Target	Buy	$117.00 ➝ $146.00	Low
11/1/2022	Piper Sandler	Boost Target		$130.00	Low
11/1/2022	BTIG Research	Boost Target		$126.00	Low
10/28/2022	Raymond James	Boost Target	Outperform	$101.00 ➝ $125.00	Low
10/28/2022	Morgan Stanley	Boost Target	Equal Weight	$107.00 ➝ $117.00	Low
10/28/2022	Wells Fargo & Company	Boost Target	Overweight	$102.00 ➝ $128.00	Low
10/28/2022	Cowen	Boost Target		$85.00 ➝ $114.00	Low
10/28/2022	Cowen	Boost Target		$85.00 ➝ $114.00	Low
10/28/2022	Citigroup	Boost Target		$105.00 ➝ $117.00	Low
10/28/2022	Robert W. Baird	Boost Target		$97.00 ➝ $120.00	Low
10/17/2022	Barclays	Initiated Coverage	Equal Weight	$103.00	Low
10/12/2022	Jefferies Financial Group	Initiated Coverage	Buy	$125.00	Low
10/11/2022	Morgan Stanley	Boost Target	Equal Weight	$83.00 ➝ $107.00	Low
10/10/2022	BTIG Research	Boost Target	Buy	$92.00 ➝ $110.00	Low
10/7/2022	Piper Sandler	Boost Target	Overweight	$110.00 ➝ $120.00	Low
10/7/2022	Stifel Nicolaus	Boost Target	Buy	$112.00 ➝ $120.00	Low
7/29/2022	Cowen	Reiterated Rating	Buy	$85.00	Low
7/29/2022	Oppenheimer	Lower Target		$131.00 ➝ $105.00	Low
7/29/2022	Wells Fargo & Company	Lower Target		$144.00 ➝ $102.00	Low
7/29/2022	Piper Sandler	Lower Target	Overweight	$120.00 ➝ $110.00	Low
7/29/2022	Morgan Stanley	Lower Target	Equal Weight	$91.00 ➝ $83.00	Low
7/29/2022	Robert W. Baird	Lower Target		$115.00 ➝ $97.00	Low
7/29/2022	Citigroup	Lower Target		$105.00 ➝ $100.00	Low
7/15/2022	Sanford C. Bernstein	Initiated Coverage	Outperform	$105.00	Low
6/24/2022	BTIG Research	Lower Target	Buy	$135.00 ➝ $105.00	Low
6/13/2022	Morgan Stanley	Lower Target	Equal Weight	$90.75	N/A
6/7/2022	Morgan Stanley	Lower Target	Equal Weight	$123.00 ➝ $90.75	Medium
5/17/2022	Citigroup	Lower Target	Buy	$157.50 ➝ $131.25	N/A
4/29/2022	SVB Leerink	Lower Target		$141.25 ➝ $125.00	High
4/29/2022	Canaccord Genuity Group	Lower Target		$131.25 ➝ $125.00	Medium
4/29/2022	Raymond James	Lower Target		$134.50 ➝ $121.50	Medium
4/29/2022	Piper Sandler	Lower Target		$181.25 ➝ $120.00	Medium
4/18/2022	BTIG Research	Boost Target		$133.75 ➝ $140.00	High
3/2/2022	Bank of America	Initiated Coverage	Buy ➝ Buy		Medium
2/11/2022	Robert W. Baird	Lower Target		$156.25 ➝ $140.00	Medium
2/11/2022	Morgan Stanley	Lower Target	Equal Weight	$142.50 ➝ $128.50	Medium
2/11/2022	Citigroup	Lower Target		$165.00 ➝ $157.50	Medium
2/3/2022	BTIG Research	Upgrade	Neutral ➝ Buy	$133.75	High
1/19/2022	Raymond James	Lower Target	Outperform	$154.50 ➝ $134.50	Low
1/19/2022	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$143.75	Low
1/7/2022	Morgan Stanley	Lower Target	Equal Weight	$144.00 ➝ $142.50	High
1/7/2022	Guggenheim	Upgrade	Neutral ➝ Buy	$145.00	High
11/1/2021	Raymond James	Boost Target	Outperform	$128.75 ➝ $154.50	Low
10/29/2021	Jefferies Financial Group	Boost Target	Buy	$152.50 ➝ $163.75	High
10/29/2021	Oppenheimer	Boost Target	Outperform	$131.25 ➝ $156.25	High
10/29/2021	SVB Leerink	Boost Target	Outperform	$125.00 ➝ $178.75	High
10/29/2021	Morgan Stanley	Boost Target	Equal Weight	$127.50 ➝ $144.00	High
10/29/2021	Citigroup	Boost Target	Buy	$157.50 ➝ $165.00	High
10/29/2021	Robert W. Baird	Boost Target	Outperform	$130.00 ➝ $156.25	High
10/29/2021	Piper Sandler	Boost Target	Overweight	$162.50 ➝ $168.75	High
10/18/2021	Guggenheim	Downgrade	Buy ➝ Neutral		Medium
10/1/2021	Citigroup	Boost Target	Buy	$132.50 ➝ $157.50	Medium
9/16/2021	Piper Sandler	Boost Target	Overweight	$137.50 ➝ $162.50	High
8/2/2021	Morgan Stanley	Boost Target	Equal Weight	$102.50 ➝ $127.50	Low
7/30/2021	Stephens	Boost Target	Overweight	$117.00 ➝ $136.50	High
7/30/2021	Wells Fargo & Company	Boost Target	Equal Weight	$95.00 ➝ $118.75	High
7/30/2021	SVB Leerink	Boost Target	Outperform	$121.25 ➝ $125.00	High
7/30/2021	Oppenheimer	Boost Target	Outperform	$125.00 ➝ $131.25	High
7/30/2021	Raymond James	Boost Target	Outperform	$116.50 ➝ $128.75	High
7/30/2021	Robert W. Baird	Boost Target	Outperform	$115.00 ➝ $130.00	High
7/30/2021	Piper Sandler	Boost Target	Overweight	$125.00 ➝ $137.50	High
7/21/2021	Cowen	Lower Target	Outperform	$135.00 ➝ $131.25	Low
7/1/2021	Stephens	Reiterated Rating	Buy	$117.00	Low
5/28/2021	Wells Fargo & Company	Upgrade	Underweight ➝ Equal Weight	$95.00	High
5/24/2021	Barclays	Initiated Coverage	Overweight	$125.00	Medium
4/30/2021	Citigroup	Boost Target		$120.00 ➝ $122.00	High
4/30/2021	Raymond James	Boost Target	Outperform	$112.25 ➝ $116.50	High
4/15/2021	Atlantic Securities	Initiated Coverage	Overweight	$109.50	Medium
2/12/2021	Citigroup	Lower Target	Buy	$121.25 ➝ $120.00	Low
2/12/2021	Oppenheimer	Boost Target	Outperform	$103.75 ➝ $112.25	Low
2/12/2021	Morgan Stanley	Boost Target	Equal Weight	$100.50 ➝ $102.50	Low
2/12/2021	Raymond James	Boost Target	Outperform	$103.75 ➝ $112.25	Low
1/29/2021	Piper Sandler	Boost Target	Overweight	$116.25 ➝ $125.00	High
1/6/2021	UBS Group	Upgrade	Neutral ➝ Buy	$102.50 ➝ $111.25	N/A
12/15/2020	Morgan Stanley	Boost Target	Equal Weight	$99.50 ➝ $100.50	Low
12/10/2020	Raymond James	Reiterated Rating	Buy		High
11/20/2020	Piper Sandler	Reiterated Rating	Buy	$116.25	Medium
10/28/2020	Stifel Nicolaus	Lower Target	Buy	$125.00 ➝ $118.75	High
10/28/2020	Raymond James	Lower Target	Outperform	$112.50 ➝ $109.50	High
10/28/2020	Morgan Stanley	Lower Target	Equal Weight	$107.00 ➝ $99.50	High
10/2/2020	Wells Fargo & Company	Downgrade	Equal Weight ➝ Underweight	$105.00 ➝ $87.50	High
7/29/2020	UBS Group	Boost Target	Neutral	$83.75 ➝ $100.00	High
7/29/2020	Morgan Stanley	Boost Target	Equal Weight	$94.25 ➝ $107.00	Low
7/29/2020	Raymond James	Boost Target	Outperform	$98.75 ➝ $112.50	Low
7/29/2020	Stifel Nicolaus	Boost Target	Buy	$96.25 ➝ $125.00	Low
7/29/2020	SVB Leerink	Boost Target	Equal Weight ➝ Outperform	$116.25 ➝ $121.25	Medium
7/29/2020	Citigroup	Boost Target	Buy	$110.00 ➝ $121.25	Medium
7/29/2020	Piper Sandler	Boost Target	Overweight	$112.50 ➝ $116.25	Medium
7/28/2020	Oppenheimer	Initiated Coverage	Buy	$90.00 ➝ $111.25	High
7/28/2020	Bank of America	Reiterated Rating	Buy	$125.00	High
7/27/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$90.00 ➝ $112.50	Medium
7/7/2020	Cowen	Boost Target	Positive ➝ Outperform	$107.50 ➝ $112.50	Low
6/17/2020	Bank of America	Boost Target	Buy	$93.75 ➝ $125.00	Low
6/9/2020	Raymond James	Boost Target	Outperform	$90.00 ➝ $98.75	High
6/3/2020	Citigroup	Boost Target	Average ➝ Buy	$90.25 ➝ $110.00	Medium
5/27/2020	Piper Sandler	Boost Target	Overweight	$93.75 ➝ $112.50	High
5/14/2020	Wells Fargo & Company	Initiated Coverage	Equal Weight	$105.00	Low
4/30/2020	UBS Group	Boost Target	Neutral	$68.75 ➝ $83.75	Medium
4/29/2020	Guggenheim	Boost Target	Buy	$96.25 ➝ $98.75	High
4/29/2020	Citigroup	Boost Target	Buy	$82.50 ➝ $90.25	High
4/29/2020	Morgan Stanley	Boost Target	Equal Weight	$69.50 ➝ $94.25	Medium
4/29/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$75.00 ➝ $90.00	Medium
4/29/2020	Stifel Nicolaus	Boost Target	Buy	$67.50 ➝ $96.25	Medium
4/29/2020	Oppenheimer	Boost Target	Outperform	$76.25 ➝ $90.00	High
4/29/2020	Cowen	Boost Target	Outperform	$75.00 ➝ $90.00	High
4/29/2020	Robert W. Baird	Boost Target	Outperform	$74.00 ➝ $93.25	High
4/29/2020	Piper Sandler	Boost Target	Overweight	$75.00 ➝ $93.75	High
4/29/2020	BTIG Research	Reiterated Rating	Hold		High
4/27/2020	Raymond James	Boost Target	Outperform	$72.00 ➝ $87.50	Low
4/24/2020	SVB Leerink	Boost Target	Outperform	$79.00 ➝ $96.25	Medium
3/27/2020	Morgan Stanley	Boost Target	Equal Weight	$67.50 ➝ $69.50	High
3/23/2020	Stephens	Lower Target	Overweight	$75.00 ➝ $60.00	Low
3/6/2020	Oppenheimer	Boost Target	Outperform	$71.25 ➝ $76.25	Low
3/4/2020	Citigroup	Initiated Coverage	Buy	$82.50 ➝ $82.50	Low
2/18/2020	Morgan Stanley	Boost Target	Equal Weight	$56.25 ➝ $67.50	High
2/14/2020	Piper Sandler	Boost Target		$57.50 ➝ $75.00	Low
2/14/2020	Cfra	Boost Target	Hold	$51.25 ➝ $64.50	High
2/14/2020	Oppenheimer	Boost Target	Outperform	$62.50 ➝ $71.25	High
2/14/2020	Cowen	Reiterated Rating	Outperform	$62.50 ➝ $75.00	High
2/14/2020	Guggenheim	Reiterated Rating	Buy	$61.25 ➝ $75.00	High
2/14/2020	Stephens	Boost Target	Overweight	$63.75 ➝ $75.00	High
2/14/2020	UBS Group	Boost Target	Neutral	$62.50 ➝ $68.75	High
2/14/2020	Raymond James	Boost Target	Outperform	$64.50 ➝ $72.00	High
2/14/2020	Stifel Nicolaus	Boost Target	Buy	$62.50 ➝ $75.00	High
1/7/2020	Cowen	Reiterated Rating	Buy	$62.50	High
12/20/2019	JPMorgan Chase & Co.	Boost Target	Overweight	$53.75 ➝ $63.75	Low
12/18/2019	Bank of America	Reiterated Rating	Buy	$55.00 ➝ $62.50	Low
12/17/2019	Morgan Stanley	Boost Target	Equal Weight	$50.50 ➝ $56.25	Medium
12/16/2019	Piper Sandler Companies	Reiterated Rating	Buy	$57.50	Medium
11/18/2019	Piper Sandler Companies	Reiterated Rating	Overweight		High
11/7/2019	Oppenheimer	Boost Target		$45.00 ➝ $51.25	Medium
11/7/2019	Raymond James	Boost Target	Outperform	$43.00 ➝ $47.25	High
11/7/2019	Robert W. Baird	Boost Target	Outperform	$48.75 ➝ $60.00	High
11/7/2019	Jefferies Financial Group	Boost Target	Buy	$45.00 ➝ $50.00	High
11/7/2019	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$47.50 ➝ $53.75	High
11/7/2019	Guggenheim	Upgrade	Neutral ➝ Buy		High
10/22/2019	Stifel Nicolaus	Initiated Coverage	Buy	$47.50	High
9/23/2019	Piper Sandler Companies	Set Target	Buy	$45.50	Medium
9/3/2019	BMO Capital Markets	Boost Target	Outperform	$45.00 ➝ $47.50	Low
8/29/2019	Robert W. Baird	Boost Target	Outperform	$46.50 ➝ $48.75	Low
8/1/2019	Oppenheimer	Boost Target		$41.75 ➝ $45.00	Medium
8/1/2019	Bank of America	Boost Target	Buy	$40.50 ➝ $46.25	Medium
8/1/2019	Robert W. Baird	Boost Target	Outperform	$45.00 ➝ $46.50	High
8/1/2019	JPMorgan Chase & Co.	Boost Target	Overweight	$42.50 ➝ $47.50	High
8/1/2019	UBS Group	Boost Target	Neutral	$35.00 ➝ $40.00	High
8/1/2019	Raymond James	Boost Target	Outperform	$37.50 ➝ $43.00	High
8/1/2019	BTIG Research	Reiterated Rating	Hold		High
7/31/2019	Piper Sandler Companies	Boost Target	Overweight ➝ Positive	$43.25 ➝ $45.50	High
7/15/2019	Piper Sandler Companies	Set Target	Buy	$43.25	High
6/6/2019	Northland Securities	Reiterated Rating	Hold	$31.25	High
5/2/2019	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$41.75 ➝ $43.00	High
5/2/2019	Raymond James	Lower Target	Outperform ➝ Outperform	$40.00 ➝ $37.50	High
5/1/2019	Piper Sandler Companies	Boost Target	Overweight	$43.25	High
4/30/2019	UBS Group	Lower Target	Neutral ➝ Neutral	$37.50 ➝ $35.00	High

(Data available from 4/26/2019 forward)

News Sentiment Rating

0.88 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

22 very positive mentions
24 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

9/29/2023

25 very positive mentions
30 positive mentions
5 negative mentions
4 very negative mentions

Mentions as of

10/29/2023

20 very positive mentions
13 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

11/28/2023

33 very positive mentions
17 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/28/2023

33 very positive mentions
21 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

1/27/2024

45 very positive mentions
32 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

2/26/2024

40 very positive mentions
30 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/27/2024

44 very positive mentions
29 positive mentions
3 negative mentions
2 very negative mentions

Mentions as of

4/26/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

benzinga.com
1 hour ago
Intel Reports Weak Sales, Joins Boyd Gaming, Atlassian And Other Big Stocks Moving Lower In Friday's Pre-Market Session
finance.yahoo.com
16 hours ago
Dexcom Plummets After Raising Its Sales Guidance For The Year — But Not Enough
finance.yahoo.com
4/19/2024
Even IBD 50 Medical Products Stocks Don't All Look Healthy In This Sick Market
investorplace.com
4/10/2024
Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In
investorplace.com
4/3/2024
7 Nasdaq Stocks to Sell in April Before They Crash & Burn

Negative

No negative mentions tracked during this time.

Positive

finance.yahoo.com
1 hour ago
Q1 2024 Dexcom Inc Earnings Call
marketbeat.com
2 hours ago
DexCom Q1 Earnings Transcript
fool.com
6 hours ago
DexCom (DXCM) Q1 2024 Earnings Call Transcript
msn.com
11 hours ago
DXCM Stock Earnings: DexCom Beats EPS, Beats Revenue for Q1 2024
finance.yahoo.com
11 hours ago
Dexcom's profit beats estimates on strong glucose monitor demand

Very Positive

americanbankingnews.com
5 hours ago
Market Impact: Analyzing Key Insights From Dexcom Inc (DXCM) Quarterly Financial Report
marketbeat.com
18 hours ago
Bailard Inc. Has $6.91 Million Position in DexCom, Inc. (NASDAQ:DXCM)
marketbeat.com
20 hours ago
DexCom Target of Unusually Large Options Trading (NASDAQ:DXCM)
marketbeat.com
4/24/2024
Lyell Wealth Management LP Has $8.72 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)
marketbeat.com
4/22/2024
DexCom, Inc. (NASDAQ:DXCM) Stake Boosted by abrdn plc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $138.01

$134.45

$139.24

50 Day Range

MA: $130.98

$114.22

$140.45

52 Week Range

Now: $138.01

$74.75

$142.00

Volume

4,198,985 shs

Average Volume

2,325,046 shs

Market Capitalization

$54.66 billion

P/E Ratio

105.35

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of DexCom?: The following equities research analysts have issued research reports on DexCom in the last year: Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., JPMorgan Chase & Co., Leerink Partnrs, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for DXCM.
What is the current price target for DexCom?: 15 Wall Street analysts have set twelve-month price targets for DexCom in the last year. Their average twelve-month price target is $141.40, suggesting a possible upside of 2.5%. Royal Bank of Canada has the highest price target set, predicting DXCM will reach $165.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $100.00 for DexCom in the next year.
View the latest price targets for DXCM.
What is the current consensus analyst rating for DexCom?: DexCom currently has 2 hold ratings, 11 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DXCM.
What other companies compete with DexCom?: Other companies that are similar to DexCom include 3M, ResMed, Baxter International, Abiomed and Insulet. Learn More about companies similar to DexCom.
How do I contact DexCom's investor relations team?: DexCom's physical mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company's listed phone number is (858) 200-0200 and its investor relations email address is [email protected]. The official website for DexCom is www.dexcom.com. Learn More about contacing DexCom investor relations.

DexCom - DXCM Stock Price Target and Predictions

Analyst Price Target for DXCM

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.88 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of DexCom?

What is the current price target for DexCom?

What is the current consensus analyst rating for DexCom?

What other companies compete with DexCom?

How do I contact DexCom's investor relations team?